Talk about pharmaceutical mergers and acquisitions in the year of the epidemic

It is said that research and development and mergers and acquisitions are the eternal topic of pharmaceutical companies.
If research and development is a way of internal exercise, then the external mergers and acquisitions of pharmaceutical companies include not only the strategic improvement of product pipelines and market expansion, but also the high level of preference and longing for innovative therapies and innovative drugs.
in recent years, some well-known pharmaceutical companies such as Lilly, Roche, Amjin, Sanofi and so on have mergers and acquisitions cases.
as recently as 2019, pharmaceutical mergers and acquisitions have been very active, with five drug mergers and acquisitions worth more than $10 billion (see table 1).
a few days ago, Bristol Myers' $13bn acquisition of MyoKardia, a drugmaker known for developing heart drugs, has raised concerns in the pharmaceutical industry.
a brief chat about pharmaceutical industry mergers and acquisitions for the period 2019-2020 below the 10 billion-dollar pharmaceutical acquisitions in 2019-2019.
Event 1 - Squipp's acquisition of New Base Pharmaceuticals is one of the world's top 10 pharmaceutical giants in oncology, with a number of heavyweight products worldwide (see table 2), including PD-1 star product Navuliyu single anti-injection (Opdivo, Chinese commodity name Odivo), 2019 With global sales of more than $7.2 billion, and especially on November 21, 2019, BMS completed a $74 billion acquisition of New Base, re-acquiring a number of promising product pipelines in the areas of oncology, immunity, and inflammation, a acquisition launched by Shi Guibao to reduce the company's reliance on cancer drugs and strengthen its position in heart disease treatment.
Table 2 - 2019 Hundreds of millions of dollars in sales of major drugs (US$100 million) event 2 - Samer Fei's acquisition of Qiagen 2020, sweeping the world's new crown epidemic has affected many industries, the community's attention to the pharmaceutical industry has increased significantly.
outbreak, the global supply of API is tight in supply and demand, the lack of pharmaceutical supplies, a number of clinical trial processes are seriously hampered, but also affect the development of innovative drugs and innovative therapies.
the crisis, there is a growing recognition of the importance of the pharmaceutical industry's supply chain, and a growing preference for innovative drugs, including vaccines, medical devices and healthcare, as can be seen from some mergers and acquisitions in 2020, such as Thermo's announcement in March 2020 that it would buy Qiagen N.V for $11.5 billion, but terminated the deal in August.
Qiagen is the world's leading provider of molecular diagnostic solutions and sample preparation technologies that extract, isolate and purify DNA, RNA and proteins in a variety of biological samples.
At the same time, QIAGEN is committed to developing a full-process solution from sample preparation to data interpretation, integrating sample processing, molecular diagnostic analysis, and bio-information technology into a complete workflow to interpret molecular diagnostic data and produce clinically significant reports.
qiagen's business prospects have improved significantly since the outbreak, with global demand for its COVID-19 diagnostic reagents and molecular testing supplies soaring, and the company's share price exceeded its initial offer, with sales up nearly 20 per cent, during which time Seymru raised its purchase price to $12.5 billion, but the acquisition was terminated.
can be seen from the above information, because of the sudden outbreak of the new crown, leading to a sharp rise in Qiagen's value is the reason for the termination of the acquisition.
the dramatic elements of this make the industry have to --- the time also? Life too? Event 3 - Gilead's acquisition of Immunomedics is by far the biggest acquisition in 2020 when Gilead announced a $21 billion acquisition of Immunomedics in September, another major acquisition of the oncology sector by Gilead after its $12 billion acquisition of CAR-T maker Kite in 2017.
Gilead is a drug company specializing in the development of antiviral drugs and has a significant influence in the treatment of AIDS and hepatitis C.
, Gilead has also made strides in areas such as cancer, gastrointestinal tract and immunity, particularly after the acquisition of CAR-T company Kite in 2017, demonstrating its commitment to entering the field of oncology.
March 2020, Gilead acquired FortySeven, a company that develops CD47 antibody drugs, for $4.9 billion; Gilead acquired a 49.9 percent stake in cancer immunotherapy developer Pionyr Immunotherapeutics for $275 million, and on July 21, 2020, Gilead announced a $300 million equity investment in Tizona Therapeutics Inc., the company that develops the first-in-class cancer immunotherapy drug.
September 2020, Gilead and Jounce Therapeutics reached an agreement to exclusively license their JTX-1811 project.
acquisition is based on the technology and prospects for Immunomedics in the next generation of antibody drug concedes (ADCs).
Immunomedics is dedicated to the development of antibody drugs and ADCs, the company's Trodelvy has been accelerated by the FDA to become the world's first antibody conjud drug to treat triple-negative breast cancer.
, Trodelvy became the first targeted drug to target Trop-2.
the future of the field of oncology may become Gilead's focus layout direction.
addition to these typical cases, here are some of the mergers and acquisitions cases for your reference in 2020.
Table 3 - 2020 Major mergers and acquisitions of global pharmaceutical companies in the first three quarters (US$100 million) can be seen from the above cases: Although in recent years, with the implementation of the new version of the Drug Administration Law, the continuous deepening and expansion of collection, resulting in some domestic small and medium-sized enterprises operating difficulties.
and with the continuous reform of the domestic registration and review system, some enterprises operating the traditional pharmaceutical industry are faced with confusion in product development and project promotion.
But in terms of the overall trend of the global pharmaceutical industry, the pharmaceutical industry is still relatively stable industry, and under the frequent and sustained impact of the new crown outbreak, the pharmaceutical industry is also part of the liquidity safe haven.
, we also believe that the outstanding part of domestic medicine--- specialty research and development enterprises and comprehensive strength of strong enterprises, even if the adjustment of policies, in the next five years of the market game, will become the winning role of this banquet.
, we also believe that in the future, international pharmaceutical mergers and acquisitions cases will be more Chinese enterprises. Introduction to
Authors: Zhulikou431, Senior Engineer, PDA Member, ISPE Member, ECA Member, PQRI Member, Senior Sterile GMP Specialist, with deep knowledge in the fields of sterile process development and verification, drug research and development and registration, CTD document writing and auditing, regulatory audit, international certification, international registration, quality system construction and maintenance, as well as sterile inspection, environmental monitoring and other fields.
recent years, we have focused on the analysis of trends in the macro-field of pharmaceutical companies and the risk management of mergers and acquisitions projects of pharmaceutical companies.